Researchers are developing techniques to genetically modify cancer-fighting immune cells directly inside patients rather than in expensive laboratory facilities, potentially making CAR-T therapy accessible to far more people.

Current CAR-T treatments require removing a patient's T cells, shipping them to specialized facilities for genetic engineering, then returning them weeks later at costs around $500,000 per dose. The new "in vivo" approaches use viral vectors or RNA-loaded nanoparticles to deliver genetic instructions directly to T cells circulating in the bloodstream, which could reduce costs by an order of magnitude. Companies including Capstan Therapeutics, co-founded by Nobel laureates, and AstraZeneca-backed EsoBiotec have launched early human trials. While only about 200 US centers currently offer traditional CAR-T therapy, the approach could make the powerful treatment available on demand like conventional drugs.

CERN's particle accelerator is being used in a pioneering cancer treatment called Flash radiotherapy. This method delivers ultra-high radiation doses in less than a second, minimizes side effects while targeting tumors more effectively than conventional radiotherapy. The BBC reports: In a series of vast underground caverns on the outskirts of Geneva, Switzerland, experiments are taking place which may one day lead to new generation of radiotherapy machines. The hope is that these devices could make it possible to cure complex brain tumors (PDF), eliminate cancers that have metastasized to distant organs, and generally limit the toll which cancer treatment exerts on the human body. The home of these experiments is the European Laboratory for Particle Physics (Cern), best known to the world as the particle physics hub that developed the Large Hadron Collider, a 27 kilometer (16.7 mile)-long ring of superconducting magnets capable of accelerating particles to near the speed of light.

Arguably Cern's crowning achievement was the 2012 discovery of the Higgs boson, the so-called "God Particle" which gives other particles their mass and in doing so lays the foundation for everything that exists in the universe. But in recent years, the centre's unique expertise in accelerating high-energy particles has found a new niche -- the world of cancer radiotherapy. Eleven years ago, Marie-Catherine Vozenin, a radiobiologist now working at Geneva University Hospitals (Hug), and others published a paper outlining a paradigm-shifting approach to traditional radiotherapy treatment which they called Flash. By delivering radiation at ultra-high dose rates, with exposures of less than a second, they showed that it was possible to destroy tumors in rodents while sparing healthy tissue. Its impact was immediate. International experts described it as a seminal breakthrough, and it galvanized fellow radiobiologists around the world to conduct their own experiments using the Flash approach to treat a wide variety of tumors in rodents, household pets, and now humans.

In recent years, animal studies have repeatedly shown that Flash makes it possible to markedly increase the amount of radiation delivered to the body while minimizing the impact that it has on surrounding healthy tissue. In one experiment, healthy lab mice which were given two rounds of radiation via Flash did not develop the typical side effects which would be expected during the second round. In another study, animals treated with Flash for head and neck cancers experienced fewer side effects, such as reduced saliva production or difficulty swallowing. Loo is cautiously optimistic that going forwards, such benefits may also translate to human patients. "Flash produces less normal tissue injury than conventional irradiation, without compromising anti-tumor efficacy -- which could be game-changing," he says. An additional hope is that this could then reduce the risk of secondary cancers (PDF), resulting from radiation-induced damage later in life, although it is still too early to know if that will be the case. [...] But the next phase of research is not only about testing whether Flash works in people. It's also about identifying which kind of radiation is the best one to use.

A University of Zagreb virologist treated her own recurring breast cancer by injecting laboratory-grown viruses into her tumor, sparking debate about self-experimentation in medical research. Beata Halassy discovered her stage 3 breast cancer in 2020 at age 49, recurring at the site of a previous mastectomy. Rather than undergo another round of chemotherapy, she developed an experimental treatment using oncolytic virotherapy (OVT).

Over two months, Halassy administered measles and vesicular stomatitis viruses directly into the tumor. The treatment caused the tumor to shrink and detach from surrounding tissue before surgical removal. Post-surgery analysis showed immune cell infiltration, suggesting the viruses had triggered an immune response against the cancer. Halassy has been cancer-free for four years. OVT remains unapproved for breast cancer treatment worldwide. Nature adds: Halassy felt a responsibility to publish her findings. But she received more than a dozen rejections from journals -- mainly, she says, because the paper, co-authored with colleagues, involved self-experimentation. "The major concern was always ethical issues," says Halassy. She was particularly determined to persevere after she came across a review highlighting the value of self-experimentation.

That journals had concerns doesn't surprise Jacob Sherkow, a law and medicine researcher at the University of Illinois Urbana-Champaign who has examined the ethics of researcher self-experimentation in relation to COVID-19 vaccines. The problem is not that Halassy used self-experimentation as such, but that publishing her results could encourage others to reject conventional treatment and try something similar, says Sherkow. People with cancer can be particularly susceptible to trying unproven treatments. Yet, he notes, it's also important to ensure that the knowledge that comes from self-experimentation isn't lost. The paper emphasizes that self-medicating with cancer-fighting viruses "should not be the first approach" in the case of a cancer diagnosis.

Phys.org reports that a newly published theoretical/computer-modeling study "suggests that the world's most powerful lasers might finally crack the elusive physics behind some of the most extreme phenomena in the universe — gamma ray bursts, pulsar magnetospheres, and more."

The study comes from an international team including researchers from Lawrence Berkeley National Laboratory and France's Alternative Energies and Atomic Energy Commission (publishing in the journal Physical Review Letters.): The team's modeling study shows that petawatt (PW)-class lasers — juiced to even higher intensities via light-matter interactions — might provide a key to unlock the mysteries of the strong-field (SF) regime of quantum electrodynamics (QED). A petawatt is 1 times ten to the fifteenth power (that is, followed by 15 zeroes), or a quadrillion watts. The output of today's most powerful lasers is measured in petawatts... "This is a powerful demonstration of how advanced simulation of complex systems can enable new paths for discovery science by integrating multiple physics processes — in this case, the laser interaction with a target and subsequent production of particles in a second target," said ATAP Division Director Cameron Geddes....

The scheme consists of boosting the intensity of a petawatt laser pulse with a relativistic plasma mirror. Such a mirror can be formed when an ultrahigh intensity laser beam hits an optically polished solid target. Due to the high laser amplitude, the solid target is fully ionized, forming a dense plasma that reflects the incident light. At the same time the reflecting surface is actually moved by the intense laser field. As a result of that motion, part of the reflected laser pulse is temporally compressed and converted to a shorter wavelength by the Doppler effect. Radiation pressure from the laser gives this plasma mirror a natural curvature. This focuses the Doppler-boosted beam to much smaller spots, which can lead to extreme intensity gains — more than three orders of magnitude — where the Doppler-boosted laser beam is focused. The simulations indicate that a secondary target at this focus would give clear SF-QED signatures in actual experiments.

The study drew upon Berkeley Lab's diverse scientific resources, including its WarpX simulation code, which was developed for modeling advanced particle accelerators under the auspices of the U.S. Department of Energy's Exascale Computing Project... The discovery via WarpX of novel high-intensity laser-plasma interaction regimes could have benefits far beyond ideas for exploring strong-field quantum electrodynamics. These include the better understanding and design of plasma-based accelerators such as those being developed at the Berkeley Lab Laser Accelerator. More compact and less expensive than conventional accelerators of similar energy, they could eventually be game-changers in applications that range from extending the reach of high-energy physics and of penetrating photon sources for precision imaging, to implanting ions in semiconductors, treating cancer, developing new pharmaceuticals, and more.

"It is gratifying to be able to contribute to the validation of new, potentially very impactful ideas via the use of our novel algorithms and codes," Vay said of the Berkeley Lab team's contributions to the study. "This is part of the beauty of collaborative team science."
Long-time Slashdot reader fahrbot-bot has suggested that the article deserves an alternate title: "Article I Read Three Times and Still Don't Completely Understand."

An anonymous reader quotes a report from The New York Times: The study, published Wednesday in the New England Journal of Medicine, found that e-cigarettes were nearly twice as effective as conventional nicotine replacement products, like patches and gum, for quitting smoking. The success rate was still low -- 18 percent among the e-cigarette group, compared to 9.9 percent among those using traditional nicotine replacement therapy -- but many researchers who study tobacco and nicotine said it gave them the clear evidence they had been looking for. The study was conducted in Britain and funded by the National Institute for Health Research and Cancer Research UK. For a year, it followed 886 smokers assigned randomly to use either e-cigarettes or traditional nicotine replacement therapies. Both groups also participated in at least four weekly counseling sessions, an element regarded as critical for success. The findings could give some new legitimacy to e-cigarette companies like Juul, which have been under fire from the government and the public for contributing to what the Food and Drug Administration has called an epidemic of vaping among teenagers. But they could also exacerbate the difficulty of keeping the devices away from young people who have never smoked while making them available for clinical use.

"Australian scientists have taken a 'major step forward' in the world of cancer research," reports ABC (the national broadcaster of Australia). Long-time Slashdot reader Artem Tashkinov quotes an announcement from the Walter and Eliza Hall Institute of Medical Research: In a world first, Melbourne scientists have discovered a new type of anti-cancer drug that can put cancer cells into a permanent sleep, without the harmful side-effects caused by conventional cancer therapies.

Published today in the journal Nature, the research reveals the first class of anti-cancer drugs that work by putting the cancer cell to sleep -- arresting tumour growth and spread without damaging the cells' DNA.

The new class of drugs could provide an exciting alternative for people with cancer, and has already shown great promise in halting cancer progression in models of blood and liver cancers, as well as in delaying cancer relapse.
One of the lead researchers says the new compounds "had already shown great promise in preclinical testing."

Sophia Chen, writing for Science magazine: On its own, a single-pixel camera captures pictures that are pretty dull: squares that are completely black, completely white, or some shade of gray in between. All it does, after all, is detect brightness. Yet by connecting a single-pixel camera to a patterned light source, a team of physicists in China has made detailed x-ray images using a statistical technique called ghost imaging, first pioneered 20 years ago in infrared and visible light. Researchers in the field say future versions of this system could take clear x-ray photographs with cheap cameras -- no need for lenses and multipixel detectors -- and less cancer-causing radiation than conventional techniques.

"Our system is much smaller and cheaper, and it could even be portable if you needed to take it into the field," says Wu Ling-An, a physicist at the Chinese Academy of Sciences in Beijing whose work with her colleagues was published on 28 March in Optica. The researchers' system still isn't ready to be used in medicine. But they have lowered the x-ray dose by about a million times compared with earlier attempts, says Daniele Pelliccia, who in 2015 made some of the first x-ray ghost images.

A national panel of public health experts concluded in a report released on Tuesday that vaping with e-cigarettes that contain nicotine can be addictive and that teenagers who use the devices may be put at higher risk of switching to traditional smoking. From a report: Whether teenage use of e-cigarettes may lead to conventional smoking has been intensely debated in the United States and elsewhere. While the industry argues that vaping is not a steppingstone to conventional cigarettes or addiction, some antismoking advocates contend that young people become hooked on nicotine, and are enticed to cancer-causing tobacco-based cigarettes over time. The new report by the National Academies of Sciences, Engineering and Medicine is the most comprehensive analysis of existing research on e-cigarettes. It concluded the devices are safer than traditional smoking products and that they do help smokers quit, citing conclusive proof that switching can reduce smokers' exposure to deadly tar, numerous dangerous chemicals and other carcinogens.

An anonymous reader quotes a report from The Guardian: A revolutionary blood test has been shown to diagnose the recurrence of cancer up to a year in advance of conventional scans in a major lung cancer trial. The test, known as a liquid biopsy, could buy crucial time for doctors by indicating that cancer is growing in the body when tumors are not yet detectable on CT scans and long before the patient becomes aware of physical symptoms. It works by detecting free-floating mutated DNA, released into the bloodstream by dying cancer cells. In the trial of 100 lung cancer patients, scientists saw precipitous rises in tumor DNA in the blood of patients who would go on to relapse months, or even a year, later. In the latest trial, reported in the journal Nature, 100 patients with non-small cell lung cancer were followed from diagnosis through surgery and chemotherapy, having blood tests every six to eight weeks. By analyzing the patchwork of genetic faults in cells across each tumor, scientists created personalized genomic templates for each patient. This was then compared to the DNA floating in their blood, to assess whether a fraction of it matched that seen in their tumor.

sciencehabit quotes a report from Science Magazine: Computer hardware is getting a softer side. A research team has come up with a way of genetically engineering the DNA of mammalian cells to carry out complex computations, in effect turning the cells into biocomputers. The group hasn't put those modified cells to work in useful ways yet, but down the road researchers hope the new programming techniques will help improve everything from cancer therapy to on-demand tissues that can replace worn-out body parts. To upgrade their DNA "switches," Wong and his colleagues steered clear of transcription factors and instead switched human kidney cell genes on and off using scissor-like enzymes that selectively cut out snippets of DNA. These enzymes, known as DNA recombinases, recognize two target stretches of DNA, each between 30 to 50 or more base pairs long. When a recombinase finds its target DNA stretches, it cuts out any DNA in between, and stitches the severed ends of the double helix back together. To design genetic circuits, Wong and his colleagues use the conventional cellular machinery that reads out a cell's DNA, transcribes its genes into RNA, and then translates the RNA into proteins. This normal gene-to-protein operation is initiated by another DNA snippet, a promoter, that sits just upstream of a gene. When a promoter is activated, a molecule called RNA polymerase gets to work, marching down the DNA strand and producing an RNA until it reaches another DNA snippet -- a termination sequence -- that tells it to stop. To make one of their simplest circuits, Wong's team inserted four extra snippets of DNA after a promoter. The main one produced green fluorescent protein (GFP), which lights up cells when it is produced. But in front of it was a termination sequence, flanked by two snippets that signaled the DNA recombinase. Wong and his team then inserted another gene in the same cell that made a modified recombinase, activated only when bound to a specific drug; without it, the recombinase wouldn't cut the DNA. When the promoter upstream of the GFP gene was activated, the RNA polymerase ran headfirst into the termination sequence, stopped reading the DNA, and didn't produce the fluorescent protein. But when the drug was added, the recombinase switched on and spliced out the termination sequence that was preventing the RNA polymerase from initiating production of GFP. Voila, the cell lit up. The approach Wong and his colleagues used worked so well that they were able to build 113 different circuits, with a 96.5% success rate. The study has been published in the journal Nature.

An anonymous reader writes: Thanks to ongoing efforts to reduce engine emissions, nowadays only 10% to 15% of particulate emissions from traffic are coming from vehicles' tailpipes. The remainder originates in tire, road surface and brake wear. A study by Victor Timmers and Peter Achten published in Atmospheric Environment has now found that the extra weight of electric vehicles causes non-tailpipe emissions to increase by about as much as the omission of the internal combustion engine saves. Atmospheric particulates have been shown to cause cancer, cardiovascular disease and respiratory diseases and are widely considered as the most harmful form of air pollution. Achten said, "We found that non-exhaust emissions, from brakes, tires and the road, are far larger than exhaust emissions in all modern cars. These are more toxic than emissions from modern engines so they are likely to be key factors in the extra heart attacks, strokes and asthma attacks seen when air pollution levels surge." The study shows that non-exhaust emissions a vehicle produces is directly related to its weight. Scientists found that electric and eco-friendly vehicles weighed around 24 percent more than conventional vehicles, which in turn contributes to more wear on the tires.

sciencehabit writes with good news involving cancer research. From the article: "Chemotherapy drugs are like a shotgun. Even though doctors are just aiming for tumors, the compounds hit a variety of other places in the body, leading to side effects like bone marrow damage and hair loss. To improve their aim, researchers have tried to package these drugs inside tiny hollow nano-sized containers that can be directed toward tumors and bypass healthy tissues. But the size, shape, and makeup of these 'nanoparticles' can drastically affect where and when they are taken up. Now, scientists have surveyed the landscape of some 100 different nanoparticle formulations and shown that when a conventional chemotherapeutic drug is packaged inside the best of these nanoparticles, it proves considerably more effective at fighting prostate cancer (summary; article paywalled) in animals than the drug alone."

sciencehabit writes "Men typically produce working sperm as long as they live, but most textbooks say female mammals are born with all the egg cells, or oocytes, they will ever have. Since 2004, however, reproductive biologist Jonathan Tilly of Massachusetts General Hospital in Boston has challenged that conventional wisdom, arguing that in mice—and perhaps also in humans—there must be an ongoing source of new eggs. Today, Tilly and his colleagues report isolating rare cells in ovarian tissue from adult women that can grow in lab dishes and form immature oocytes. The potential egg stem cells could help scientists devise new ways to help rescue the fertility of women who have to undergo cancer treatments or who suffer from premature menopause."

ananyo writes "Norway is set to become the first country to incorporate genome sequencing into its national health-care system. The Scandinavian nation, which has a population of 4.8 million, will use 'next-generation' DNA sequencers to trawl for mutations in tumors that might reveal which cancer treatments would be most effective. In its three-year pilot phase, the Norwegian Cancer Genomics Consortium will sequence the tumor genomes of 1,000 patients in the hope of influencing their treatments. It will also look at another 3,000 previously obtained tumor biopsies to get a better idea of the mutations in different cancers, and how they influence a patient's response to a drug. In a second phase, the project will build the laboratory, clinical and computing infrastructure needed to bring such care to the 25,000 Norwegians who are diagnosed with cancer each year. Similar projects are under way in the United Kingdom and at research hospitals in the United States, France and elsewhere. But Norway's will be among the first to look for tumor mutations using next-generation DNA sequencing rather than conventional genetic testing."

An anonymous reader sends this quote from Wired: "By harnessing the power of tiny waves dancing in an electron sea, Japanese physicists have developed a novel way to project holograms that don't change color when you move your head. 'In a conventional hologram, if you change the angle, the color changes,' said optical physicist Satoshi Kawata of Osaka University in Japan. 'Our hologram shows natural color at any angle you observe.' The researchers’ machine takes advantage of how beams of light trigger waves of activity in free electrons, unattached to any atom, arrayed on a metal surface. Called surface plasmons, these waves could be used to blast cancer cells and build ultra-fast computer processors. They also show up in medieval stained glass windows, where plasmons on flecks of gold suspended in the glass make the window change color as the sun sets."

Velcroman1 writes "Two scientists at Yale University have built the laser's first doppelganger: the anti-laser. While a conventional laser emits a constant beam of light in one direction, the anti-laser simply does the opposite. It takes that same steady light stream and interacts with it in such a way that it absorbs and cancels out the light. And scientists hope the strange creation could help the fight against cancer. A. Douglas Stone, one of the two researchers behind the project, said he came up with the idea for a 'nega-laser' when working with equations for a random laser with his partner in crime, Hui Cao. 'I figured, if we just somehow illuminated the cavity, and replaced the gain medium with something that tends to absorb light, we could essentially reverse the process,' Stone said. Oh, that makes sense."

Roland Piquepaille writes "The Cyberknife is not a real knife. This is a robot radiotherapy machine which works with great accuracy during treatment, thanks to its robotic arm which moves around a patient when he breathes. According to BBC News, the first Cyberknife will be operational in February 2009 in London, UK. But other machines have been installed in more than 15 countries, and have permitted doctors to treat 50,000 patients in the first semester of 2008. And the Cyberknife is more efficient than conventional radiotherapy devices. The current systems require twenty or more short sessions with low-dose radiation. On the contrary, and because it's extremely precise, a Cyberknife can deliver powerful radiation in just three sessions."

Wow. More politicians (of all parties) need to be as open and thorough as Steve Novick is here. We selected 10 of the questions you submitted and sent them to him by email, and his responses... let's just say that if every candidate spoke out like Steve, we'd have a much clearer view of our choices and would be able to cast our votes a lot more rationally.

The feed points us to a NYTimes article about hospitals using particle accelerators to treat cancer. While expensive, proponents say that the proton beams generated by the accelerators are more precise than conventional X-ray radiation therapy. This results in fewer side effects and reduced irradiation of surrounding tissue. The technology's critics say that the cost is not justified by a measurable increase in the level of care given to the patients. Nevertheless, this is an excellent example of "pure scientific research" leading to a useful, unrelated technique. From the NYTimes: "Tumors in or near the eye, for instance, can be eradicated by protons without destroying vision or irradiating the brain. Protons are also valuable for treating tumors in brains, necks and spines, and tumors in children, who are especially sensitive to the side effects of radiation."

Stony Stevenson writes "Canadian researchers have promised to squeeze "decades" of cancer research into just two years by harnessing the power of a global PC grid. The scientists are the first from Canada to use IBM's World Community Grid network of PCs and laptops with the power equivalent to one of the globe's top five fastest supercomputers. The team will use the grid to analyze the results of experiments on proteins using data collected by scientists at the Hauptman-Woodward Medical Research Institute in Buffalo, New York. The researchers estimate that this analysis would take conventional computer systems 162 years to complete."